2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-179823A
    C18(2S-OH) Galactosyl(β) ceramide 168395-96-8 98%
    C18(2S-OH) Galactosyl(β) ceramide is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.
    C18(2S-OH) Galactosyl(β) ceramide
  • HY-179952A
    12:0 (2S-OH) Ceramide 1246298-45-2 98%
    12:0 (2S-OH) Ceramide is a ceramide.
    12:0 (2S-OH) Ceramide
  • HY-18260S4
    Bisphenol A-d4 102438-62-0 98%
    Bisphenol A-d4 is the deuterium labeled Bisphenol A. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders.
    Bisphenol A-d4
  • HY-185229A
    CTR/AMYR agonist-1 enantiomer 3108097-24-8 98%
    CTR/AMYR agonist-1 enantiomer is an enantiomer of CTR/AMYR agonist-1 (HY-185229). CTR/AMYR agonist-1 is a CTR/AMYR agonist with EC50 values of 0.56-6.9 nM. CTR/AMYR agonist-1 can be used for the research of metabolic disease.
    CTR/AMYR agonist-1 enantiomer
  • HY-18734AR
    Carboxy-PTIO potassium (Standard) 148819-94-7
    Carboxy-PTIO (potassium) (Standard) is the analytical standard of Carboxy-PTIO (potassium). This product is intended for research and analytical applications. Carboxy-PTIO potassium is a potent nitric oxide (NO) scavenger that can make a quick reaction with NO to produce NO2. Carboxy-PTIO potassium can prevent hypotension and endotoxic shock through the direct scavenging action against NO in lipopolysaccharide-stimulated rat model.
    Carboxy-PTIO potassium (Standard)
  • HY-19727AR
    FOY 251 (Standard) 71079-09-9
    FOY 251 (Standard) is the analytical standard of FOY 251. This product is intended for research and analytical applications. FOY 251, an anti-proteolytic active metabolite Camostate (HY-13512), acts as a proteinase inhibitor. FOY 251 inhibits SARS-CoV-2 infection in cells assay.
    FOY 251 (Standard)
  • HY-32348S1
    Doxercalciferol-d6 98%
    Doxercalciferol-d6 (1.alpha.-Hydroxyvitamin D2-d6) is deuterium labeled Doxercalciferol. Doxercalciferol is a Vitamin D2 analog, acts as an activator of Vitamin D receptor, and prevent renal disease.
    Doxercalciferol-d6
  • HY-32350S1
    Ercalcitriol-d3 1261254-46-9 98%
    Ercalcitriol-d3 (1α,25-Dihydroxy Vitamin D2-d3) is the deuterium labeled Ercalcitriol (HY-32350). Ercalcitriol (1α,25-Dihydroxy Vitamin D2) is a vitamin D receptor (VDR) agonist with high binding affinity. After binding to VDR, Ercalcitriol forms a complex with retinoid X receptor (RXR) to regulate target gene transcription. For example, Ercalcitriol induces human gingival/oral epithelial cells to produce human cat antimicrobial peptide (hCAP-18/LL-37), which has antimicrobial activity against periodontal pathogens such as Porphyromonas gingivalis. Ercalcitriol enhances the innate immune defense of the oral mucosa by promoting the expression of antimicrobial peptides, and is mainly used in the study of periodontal diseases and immune-related oral diseases.
    Ercalcitriol-d3
  • HY-32351AR
    Calcifediol monohydrate (Standard) 63283-36-3
    Calcifediol monohydrate (Standard) is the analytical standard of Calcifediol (monohydrate). This product is intended for research and analytical applications. Calcifediol monohydrate (25-hydroxy Vitamin D3 monohydrate), is an effective VDR ligand and VD supplement. Calcifediol is a prohormone of the vitamin D endocrine system (VDES) and is hydroxylated in the liver to produce the active form, calcitriol. Calcifediol can rapidly increase serum VD levels.
    Calcifediol monohydrate (Standard)
  • HY-34439S1
    2,5-Dimethylpyrazine-d3 1335401-78-9 98%
    2,5-Dimethylpyrazine-d3 is deuterated labeled 2,5-Dimethylpyrazine (HY-34439). 2,5-Dimethylpyrazine is an endogenous metabolite.
    2,5-Dimethylpyrazine-d3
  • HY-76847S4
    Chenodeoxycholic acid-d2 57770-00-0 98%
    Chenodeoxycholic acid-d2 (CDCA-d2) is deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.
    Chenodeoxycholic acid-d2
  • HY-79593S2
    MRE-269-d7 1265295-20-2 99.59%
    MRE-269-d7 is deuterium labeled MRE-269 (HY-79593). MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist.
    MRE-269-d7
  • HY-A0023AR
    Alogliptin (Standard) 850649-61-5 98%
    Alogliptin (Standard) is the analytical standard of Alogliptin. This product is intended for research and analytical applications. Alogliptin (SYR-322 free base) is a potent, selective and orally active inhibitor of DPP-4 with an IC50 of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin can be used for the research of type 2 diabetes.
    Alogliptin (Standard)
  • HY-A0132S8
    N-Acetyl-D-glucosamine-13C,15N 478529-40-7 98%
    N-Acetyl-D-glucosamine-13C,15N is the 13C and 15N labeled N-Acetyl-D-glucosamine. N-Acetyl-D-Glucosamine (N-Acetyl-2-amino-2-deoxy-D-glucose) is a monosaccharide derivative of gluc.
    N-Acetyl-D-glucosamine-13C,15N
  • HY-B0104S3
    Glimepiride-d4-2 1131981-32-2 98%
    Glimepiride-d4-2 (GliAmperide-d4-2) is deuterium labeled Glimepiride. Glimepiride (Glimperide) is a medium-to-long acting sulfonylurea anti-diabetic compound with an ED50 of 182 μg/kg.
    Glimepiride-d4-2
  • HY-B0113S4
    Omeprazole-d3 sodium 98%
    Omeprazole-d3 sodium is deuterated labeled Omeprazole (HY-B0113). Omeprazole sodium (H 16868) is an orally active H+,K+-ATPase inhibitor and a proton pump inhibitor. Omeprazole sodium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sodium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sodium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sodium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sodium aslo has neuroprotective and antibacterial effects.
    Omeprazole-d3 sodium
  • HY-B0113S5
    Omeprazole-d6 922731-02-0 98%
    Omeprazole-d6 (H 16868-d6) is deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H+,K+-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects.
    Omeprazole-d6
  • HY-B0135AR
    Furosemide sodium (Standard) 41733-55-5 98%
    Furosemide (sodium) (Standard) is the analytical standard of Furosemide (sodium). This product is intended for research and analytical applications. Furosemide sodium is a potent and orally active inhibitor of Na+/K+/2Cl- (NKCC) cotransporter, NKCC1 and NKCC2. Furosemide sodium is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide sodium acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema.
    Furosemide sodium (Standard)
  • HY-B0144AR
    Pitavastatin (Standard) 147511-69-1 98%
    Pitavastatin (Standard) is the analytical standard of Pitavastatin. This product is intended for research and analytical applications. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects.
    Pitavastatin (Standard)
  • HY-B0162AR
    Ivabradine hydrochloride (Standard) 148849-67-6 98%
    Ivabradine hydrochloride (Standard) is the analytical standard of Ivabradine hydrochloride. This product is intended for research and analytical applications. Ivabradine hydrochloride is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine hydrochloride reduces dose-dependently heart rate without modification of blood pressure. Ivabradine hydrochloride shows anticonvulsant, anti-ischaemic and anti-anginal activity.
    Ivabradine hydrochloride (Standard)
Cat. No. Product Name / Synonyms Application Reactivity